This study was carried out at Tongji Hospital (Qiaokou cohort, the largest hospital in central China) and Sino-French New City Hospital (Caidian cohort, a branch hospital of Tongji Hospital). Subjects in Qiaokou cohort were enrolled between January 2013 and October 2019; and those in Caidian cohort were enrolled from January 2017 to October 2019. All participants were recruited based on positive T-SPOT results. BRE was performed in all subjects simultaneously. ATB was diagnosed as having positive results of Xpert MTB/RIF, and/or Mtb culture (Mycobacterial Growth Indicator Tube 960 and Lowenstein-Jensen media) in sputum, bronchoalveolar lavage fluid, or biopsy tissue, with clinical symptoms and radiological characteristics suggestive of TB. Individuals with positive T-SPOT results but without clinical or radiographic evidence of ATB were defined as LTBI. The exclusion criteria were as follows: (1) patients younger than 17 years of age and (2) patients undergoing anti-TB treatment. This study was approved by the Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.